|
| 37485873 | CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. | | 2023 |
| 35567778 | Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. | American Journal of Hematology | 2023 |
| 37653344 | Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. | Nat Med | 2023 |
| 36909542 | Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia. | | 2023 |
| 37149674 | Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. | | 2023 |
| 36712071 | Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens. | bioRxiv | 2023 |
| 37315179 | Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens. | Blood Adv | 2023 |
| 36996290 | Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes. | | 2023 |
| 37114426 | Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. | | 2023 |
| 36464325 | Identifying monoclonal gammopathy of undetermined significance from electronic health records. | Cancer Reports | 2023 |
| 36460820 | DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma. | Bone Marrow Transplantation | 2023 |
| 37516547 | Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. | | 2023 |
| 37492991 | Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma. | | 2023 |
| 34822128 | Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. | Clinical Drug Investigation | 2022 |
| 35846215 | Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. | | 2022 |
| 36329525 | Telehealth exercise to Improve Physical function and frailty in patients with multiple myeloma treated with autologous hematopoietic Stem cell transplantation (TIPS): protocol of a randomized controlled trial. | Trials | 2022 |
| 36194487 | IFITM3 regulates fibrinogen endocytosis and platelet reactivity in nonviral sepsis. | J Clin Invest | 2022 |
| 35661166 | Teclistamab in Relapsed or Refractory Multiple Myeloma. | New England Journal of Medicine | 2022 |
| 36507686 | Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. | | 2022 |
| 35145071 | Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). | Blood Cancer J | 2022 |
| 35114152 | Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. | Lancet Haematol | 2022 |
| 34755136 | Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. | Cell Rep Med | 2021 |
| 32296125 | Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. | Leukemia | 2021 |
| 34010043 | When and How to Treat Relapsed Multiple Myeloma. | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting | 2021 |
| 33738338 | Oncolytic herpes simplex virus infects myeloma cells <i>in vitro</i> and <i>in vivo</i>. | Mol Ther Oncolytics | 2021 |
| 34274290 | Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2021 |
| 33465053 | CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. | JCI insight | 2021 |
| 32778736 | International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. | Leukemia | 2021 |
| 34680320 | A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. | Cancers | 2021 |
| 34388396 | Teclistamab, a B-cell maturation antigen⿿ÿ⿿CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. | Lancet, The | 2021 |
| 34899115 | Camouflaged Hybrid Cancer Cell-Platelet Fusion Membrane Nanovesicles Deliver Therapeutic MicroRNAs to Presensitize Triple-Negative Breast Cancer to Doxorubicin. | Advanced Functional Materials | 2021 |
| 34539628 | Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. | Frontiers in Immunology | 2021 |
| 32661116 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. | Journal for ImmunoTherapy of Cancer | 2020 |
| 32268821 | Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. | Leuk Lymphoma | 2020 |
| 32078124 | Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. | Advances in Therapy | 2020 |
| 32249196 | Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |
| 32286506 | Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. | Bone Marrow Transplantation | 2020 |
| 31756536 | Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. | Biology of Blood and Marrow Transplantation | 2020 |
| 32470436 | Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma? | Lancet Haematology,The | 2020 |
| 33095874 | Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. | Blood advances | 2020 |
| 32631779 | Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |
| 30940637 | Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. | Blood advances | 2019 |
| 30408566 | Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. | Biology of Blood and Marrow Transplantation | 2019 |
| 30026571 | Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. | Leukemia | 2019 |
| 30653422 | Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. | Journal of Clinical Oncology | 2019 |
| 31445185 | Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. | Biology of Blood and Marrow Transplantation | 2019 |
| 30718503 | Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. | Blood Cancer Journal | 2019 |
| 29061640 | Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. | Clinical Cancer Research | 2018 |
| 32082000 | Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. | Leukemia | 2018 |
| 30395359 | Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. | Cancer | 2018 |